Hi everyone, I'm Nicola Tangan, the CEO of the Norwegian sovereign wealth fund.

And today I'm in really good company with Emma Walmsley, the CEO of GSK, one of the global leaders in pharmaceuticals.

Now, we own 1.7% of GSK valued at 1.3 billion US dollars. Emma, great to have you here.

Wonderful to be here. Thanks for him. I believe this is the second podcast ever in your life.

The second ever. Wow. Looking forward to very much the conversation.

Now, which areas of research excites you the most just now?

Well, I'm excited about a lot of the ways that research, both in science and technology,

who are advancing, particularly those two things together. I mean, it is literally the point of

our company is to innovate and that's where

we allocate most of our capitals. So in fact, since I've been in this job, I think we've

nearly doubled our R&D spend organically and then, of course, opened up a huge amounts of

partnerships that we do externally in business development to supplement the pipeline.

What excites me most is when we can innovate in a way that has real impact at scale for patients around the world.

So I'm incredibly excited about five new approvals for new drugs and vaccines that we're expecting to get this year,

one down and another four to go.

And that's the first wave of a cohort of, we think,

14 scale medicines and vaccines, each of the potential of more than two billion pounds worth

of sales that we expect to launch this decade. And that includes in areas of oncology,

and infectious diseases, in respiratory immunology, in HIV.

And, you know, some of these, what's really exciting is when you have totally new technology

platforms in pharmaceuticals.

So, for example, in multiple myeloma, very nasty blood cancer that, where there are 180,000 new diagnoses every year, we have a new technology platform, something called antibody drug conjugates.

...